November 25, 2021 | Digital, digital health, telehealth, webinar
Research Partnership investigate the current landscape, the challenges to adoption and the future for telehealth.
Watch this webcast, in which Director, An-hwa Lee and Associate Director, Marietta Fernandes investigate the current landscape, the challenges to adoption and the future for telehealth.
They discuss what this means in terms of the new business questions for pharma. Using case studies from recent projects, they demonstrate how immersive, real-world market research techniques can be used to understand stakeholder needs and perceptions of telehealth propositions, in order to provide insights into optimal design and delivery.
View here: https://bit.ly/3FMHWBL
This content was provided by Inizio
Latest Content from Inizio
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
